“In terms of chemotherapy, we currently have gemcitabine, nab-paclitaxel [Abraxane], and FOLFIRINOX [leucovorin/5-fluorouracil (5-FU)/irinotecan/oxaliplatin]. However, these therapies are for patients with good performance status; they’re not for all patients,” Berlin explained. “Looking forward, I believe that…there is a potential role for nanoliposomal irinotecan, either in the first-line setting, if the NAPOLI-3 trial turns out positive, or certainly after gemcitabine-based chemotherapy, due to results from the NAPOLI-1 trial. Read more . . .
The treatment arsenal for pancreatic cancer has been historically limited, with chemotherapy serving as the strongest weapon of choice, according to Jordan D. Berlin, MD; however, now, targeted agents are emerging for certain subsets of patients and a key focus of research has been focused on determining the role of nanoliposomal irinotecan (Onivyde) in the paradigm.